Evgen Pharma Plc (LON:EVG) CEO Dr Stephen Franklin discusses SFX-01 and it’s multiple applications, the “broccoli drug” and what is after SFX-01.
Stephen, the founder of Evgen Pharma, has over 20 years’ commercial experience in life science industries, focusing on the commercialisation of new technology. He was the founder of Provexis plc, a nutraceutical company, and was its chief executive at the time of its admission to AIM in 2005. Prior to that, Stephen was a principal executive with ANGLE plc, the AIM quoted technology commercialisation company, having previously held a business development role with Manchester Biotech (now University of Manchester Innovation Company), one of the largest campus-based incubators in Europe; in these roles he helped establish a portfolio of drug discovery and development businesses. Stephen has a BSc in Biology (York), a PhD in Applied Biochemistry (Nottingham) and an MBA with distinction (Nottingham). He is a Fellow of the Royal Society of Medicine and an alumni of the Royal Commission for the Exhibition of 1851.
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
